Plain-English translation of NCT06682195 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining standard chemotherapy drugs with a newer immunotherapy medication called Toripalimab can help women with triple-negative breast cancer. The treatment is given before surgery to shrink the tumor, with the goal of achieving a complete response where no cancer cells remain. This is a phase 2 trial, which means researchers are evaluating how well the combination works and what side effects patients experience.
Triple-negative breast cancer is an aggressive type that doesn't respond to some common hormone-based treatments. Researchers want to see if adding immunotherapy—which helps the immune system fight cancer—to standard chemotherapy before surgery can improve how many patients have no cancer remaining after treatment and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous chemotherapy combined with the immunotherapy medication every 3 weeks for about 12 weeks total (two phases of 6 weeks each). After 4 cycles, you would have surgery to remove the breast cancer. Following surgery, treatment continues based on your pathology results: if no cancer cells remain, you receive the immunotherapy alone for up to 1 year; if cancer cells remain, you continue combined chemotherapy and immunotherapy. You will also have gene testing on your biopsy tissue and blood samples collected throughout the study.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China